HXN-2003 / Earendil Labs - LARVOL DELTA

A novel bispecific antibody-drug conjugate targeting CEACAM5 and CDH17 exhibits potent anti-tumor activity and enhanced tumor-selectivity (AACR 2026) - "The cell binding and internalization activities of the bsAb were compared to a panel of monoclonal antibodies, including M9140 analog (an anti-CEACAM5 monoclonal antibody) and TORL-3-600 analog (an anti-CDH17 monoclonal antibody), using multiple colorectal and pancreatic cancer cell lines, The bsAb was conjugated to various topoisomerase I inhibitor payloads to generate several bispecific ADC molecules (bsADCs). Furthermore, the candidate exhibited favorable stability in human/cynomolgus plasma and good pharmacokinetic profile and tolerability in SD rats and cynomolgus monkeys. Taken together, these data support further development and broad utility of this bsADC for GI cancer treatment."

ADC • Bispecific • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CDH17 • CEACAM5